Abstract:Background: Interleukin (IL)-12 and 23 are heterodimeric cytokines composed of a common p40 subunit and p35 and p19 subunits, respectively.IL-23 is strongly implicated in the pathogenesis of inflammatory bowel disease.Aim: The aim of this study is to characterize the molecular regulation of Il23a gene expression and promoter activation in murine macrophages and experimental colitis.Results: Interferon-γ (IFN-γ) inhibits LPS-induced Il23a mRNA and IL-23 protein expression in murine bone marrow-derived macrophages (BMMs).A conserved nucleotide sequence across multiple species was identified in the promoter of the Il23a gene that contains an interferon stimulated response element (ISRE).In LPS and IFN-γ activated BMMs, chromatin immunoprecipitation and electrophoretic mobility shift assays demonstrate that interferon regulatory factors (IRFs) interact with this ISRE.Using a 1.8 kb murine Il23a luciferase reporter plasmid, LPS induces and IFN-γ inhibits LPSinduced p19 promoter activity in BMMs.Mutations in the ISRE abrogate IFN-γ inhibition of LPS-induced promoter activity.To understand the contribution of specific IRFs, IRF-1 was inhibited in BMMs by siRNA and experiments were performed in IRF-1 deficient (-/-) macrophages.IRF-1 knockdown and IRF-1-/-BMMs demonstrate increased LPS-induced IL-23 expression.Primary response genes have promoters that either exist in an open chromatin structure or undergo rapid nucleosomal remodeling.In contrast, secondary response genes with delayed induction kinetics require new protein synthesis prior to transcription initiation.Il23a expression in LPS-activated BMMs demonstrates rapid induction kinetics and unlike Il12b (established secondary response gene) is not dependent on new protein synthesis.Interestingly, LPS plus IFN-γ activated BMMs demonstrate loss of the IFN-γ inhibitory effect, suggesting IFN-γ mediated regulation of Il23a requires new protein synthesis.Il23a regulation was then studied in murine colitis models.Following intrarectal administration of TNBS, IRF-1-/-mice exhibit increased inflammation and increased colonic IL-23 expression compared to wild type (WT) mice.Additionally, we demonstrate mucosal regulation of IL-23 by the enteric microbiota using germ-free and conventionalized WT and colitis-prone IL-10-/-mice.Enteric bacteria induce significantly higher intestinal IL-23 expression in IL-10-/-mice compared with WT mice.Conclusions: IFN-γ and IRF-1 negatively regulate Il23a in murine macrophages and experimental colitis.Regulation of intestinal Il23a by the enteric microflora is a significant event in the initiation of chronic intestinal inflammation.

Dual Tnf-Alpha/Il-12p40 Interference As A Strategy To Protect Against Colitis Based On Mir-16 Precursors With Macrophage Targeting Vectors

Dual TNF-α/IL-12p40 Interference as a Strategy to Protect Against Colitis Based on miR-16 Precursors With Macrophage Targeting Vectors.

<i>Lactobacillus johnsonii</i> alleviates colitis by TLR1/2-STAT3 mediated CD206 <sup>+</sup> macrophages <sup>IL-10</sup> activation

Relationship between anti-tumor necrosis factor -α monoclonal antibody and chronic colitis in mice.

<i>Lactobacillus johnsonii</i> alleviates colitis by TLR1/2-STAT3 mediated CD206<SUP>+</SUP> macrophages<SUP>IL-10</SUP> activation

Blockage of Tumor Necrosis Factor Prevents Intestinal Mucosal Inflammation Through Down-Regulation of Interleukin-23 Secretion

Effect of Anti-Tnf-α Antibody on Mucosal Lymphocyte Apoptosis in Chronic Colitis Mice

Targeting delivery of anti-TNFalpha oligonucleotide into activated colonic macrophages protects against experimental colitis.

Targeting of MyD88 Homodimerization by Novel Synthetic Inhibitor TJ-M2010-5 in Preventing Colitis-Associated Colorectal Cancer.

Prevention of Experimental Colitis in SCID Mice Reconstituted with CD45RBhigh CD4+ T Cells by Blocking the CD40-CD154 Interactions1

Blockade of CD28/CTLA-4-B7 Costimulatory Pathway in Colitic SCID Mice

Recombinant Tumor Necrosis Factor Alpha (TNF alpha) Peptide-Based Vaccine Ameliorates Acute and Chronic Murine Colitis

Anti-mouse CD52 Treatment Ameliorates Colitis Through Suppressing Th1/17 Mediated Inflammation and Promoting Tregs Differentiation in IL-10 Deficient Mice

An Orally Administrated Nucleotide-Delivery Vehicle Targeting Colonic Macrophages for the Treatment of Inflammatory Bowel Disease

TNFα gene silencing mediated by orally targeted nanoparticles combined with interleukin-22 for synergistic combination therapy of ulcerative colitis.

Blocking Tnf-Alpha By Combination Of Tnf-Alpha- And Tnfr-Binding Cyclic Peptide Ameliorates The Severity Of Tnbs-Induced Colitis In Rats

Targeted V-type peptide-decorated nanoparticles prevent colitis by inhibiting endosomal TLR signaling and modulating intestinal macrophage polarization

Curcumin Alleviated Dextran Sulfate Sodium-Induced Colitis by Regulating M1/M2 Macrophage Polarization and TLRs Signaling Pathway

Tectorigenin inhibits inflammatory responses in murine inflammatory bowel disease and LPS-stimulated macrophages via inactivating MAPK signaling pathway

OP26 Programmable probiotic local delivery of anti-TNF-α nanobody to alleviate DSS-induced colitis

Clophosome Alleviate Dextran Sulphate Sodium‐induced Colitis by Regulating Gut Immune Responses and Maintaining Intestinal Integrity in Mice